Cardiac valvulotomes are specialized surgical instruments used for cutting abnormal heart valves during cardiac valve repair or replacement procedures. The growth of the cardiac valvulotome market is driven by the increasing prevalence of cardiovascular diseases globally that often require surgical intervention for valve repair or replacement.
The global cardiac valvulotome market is estimated to be valued at US$ 157.2 Mn in 2024 and is expected to exhibit a CAGR of 4.5% over the forecast period 2024 to 2031.
Key Takeaways
Key players: Key players operating in the Cardiac Valvulotome Market Demand are LeMaitre, INVAMED, GeoSurgical, LimFlow, Inc., B. Braun SE, Teleflex Incorporated, StarFish Product Engineering Inc., Koven Technology Canada Inc., Andramed, Zgrum Medical, BD, PEAK SURGICAL, and Symmetry Surgical Inc. LeMaitre and B. Braun SE collectively hold over 45% of the global market share.
Key opportunities: The increasing adoption of minimally invasive surgical procedures presents significant growth opportunities for manufacturers of cardiac valvulotomes used in transcatheter procedures. Additionally, growing healthcare expenditure in emerging economies will further support market expansion.
Global expansion: Major players are focusing on strengthening their presence in high growth markets such as China, India, Brazil, and Mexico through partnerships with regional medical device distributors. Companies are also investing in R&D to develop next-generation valvulotomes compatible with emerging valve treatment technologies.
Market drivers:
- Rising disease burden of rheumatic heart disease and calcific aortic stenosis: These conditions often lead to valve stenosis requiring valvuloplasty or valve replacement surgery, thereby driving demand for cardiac valvulotomes.
- Increasing focus on transcatheter aortic valve replacement (TAVR) procedures: TAVR is fast gaining preference over open-heart surgery due to its minimally invasive nature. This is positively impacting the sales of valvulotomes.
Market restraints:
- High cost of valve replacement surgery: The financial burden associated with the overall cost of surgery may limit the adoption of valve replacement, thereby having a negative influence on cardiac valvulotome sales.
- Limited reimbursement for TAVR in developing regions: Restricted or absence of insurance coverage for expensive TAVR procedures in developing countries can hinder market revenue growth in the long run.
Segment Analysis
The cardiac valvulotome market is dominated by the reusable valvulotome sub segment. Reusable valvulotomes account for over 65% of the total cardiac valvulotome market share. Reusable valvulotomes offer significant cost savings over single-use valvulotomes as they can be reused multiple times after sterilization. They also have a minimal environmental footprint compared to single-use devices. However, single-use valvulotomes are gaining market share due to concerns over cross-contamination associated with reusable devices.
Global Analysis
The North America region currently dominates the global cardiac valvulotome market with the highest market share of over 35% in 2024. This is primarily attributed to the rising geriatric population, high prevalence of valvular heart diseases, advanced healthcare facilities, and growing awareness about transcatheter aortic valve replacement (TAVR) procedures in the region. The Asia Pacific region is projected to witness the highest CAGR during the forecast period owing to rapidly improving medical technologies, increasing healthcare spending, and growing focus of global market players in emerging countries. Rising medical tourism in countries such as India and Thailand is also bolstering regional market growth.
Get more insights on Cardiac Valvulotome Market
Comments
0 comment